Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the B. Riley Securities’ Virtual Neuroscience Conference on Wednesday, April 28, 2021 at 12:00 p.m. EDT.

A live audio webcast will be available on https://www.webcaster4.com/Webcast/Page/2433/41061 or in the Investors section of the Company’s website at www.anavex.com. An audio archive of the session will also be available on the website.